Cardiovascular Diseases Research — CFDA 93.837

Heart-disease research dollars at $24.3 billion

USAspending.gov records $24,340,828,120.12 in obligations under CFDA 93.837. Eleven thousand two hundred eighty-five awards produce that stock. A simple average is about $2.16 million per award, typical of multi-year research-project assistance. The assistance-listing title is CARDIOVASCULAR DISEASES RESEARCH; CFDA 93.837 is the number that has to appear on an award for it to land in this total.

Supplements, competing renewals, and related award actions can each count as a row, which is why award count runs well ahead of recipient count. The packet does not split those action types.

USAspending.gov is the source for every figure on this page: $24,340,828,120.12 in obligations, 11,285 awards, 920 recipients, and 51 states. A university press office that quotes a different cardiovascular-research total is often mixing fiscal years, mixing expenditure accounting with obligations, or rolling in other CFDA numbers. This write-up stays on 93.837 as indexed. The $24.3 billion headline is the assistance-award stock, not a grade of the science and not cash already drawn.

Nine hundred twenty recipients in 51 states

Nine hundred twenty recipients share 11,285 awards, or about 12 award records per recipient on average. Splitting $24.3 billion evenly would assign about $26.5 million per recipient. Large medical centers often hold many concurrent 93.837 awards; the extract reports the count, not a concentration index.

Fifty-one states in the geographic count is a nationwide-minus-a-few-labels pattern in the USAspending state field. It does not mean cardiovascular-research dollars track heart-disease mortality by state. Place-of-performance follows coded recipient locations, which can cluster in research metros.

Research CFDA, not a treatment ledger

CFDA 93.837 sizes assistance tagged as cardiovascular diseases research. It does not count stents placed, guidelines issued, or deaths averted. The four facts are dollars, awards, recipients, and states. Other disease-specific research listings — aging, diabetes, neuroscience — remain separate CFDAs.

Adding those listings to 93.837 would invent a combined biomedical-research total this packet does not contain. Keep the $24.3 billion attached to 93.837 only.

Obligations versus laboratory draws

The $24.3 billion is an obligation total from USAspending.gov. Outlays on research awards usually trail as institutions draw over a project period. This page does not publish a spend-down. Closeout deobligations reduce the stock; new awards increase it.

When an institution’s ledger disagrees with USAspending, filter to CFDA 93.837 and to obligations rather than expenditures. Those two checks remove most false conflicts.

Opening the 93.837 table

The Cardiovascular Diseases Research program page overlays these aggregates. The all-programs index ranks 93.837 among other assistance listings. Agency pages show awarding-agency rollups that may include this CFDA among other research listings. For 93.837 only, use the program page.

CFDA 93.837’s $24,340,828,120.12 is an extramural research stock: 11,285 awards, 920 recipients, 51 states, sourced from USAspending.gov. The 920 named organizations are the institutional dimension; the 11,285 rows include the supplements and renewals that inflate award count relative to recipient count. Fifty-one geographic labels do not track heart-disease mortality. Keep those units separate when citing the listing.

Clinical-trial counts, stent procedures, and laboratory outlays are not in the four facts. Other disease-research listings remain separate CFDA rows. The Cardiovascular Diseases Research program page is the overlay for 93.837. The programs index ranks it by obligation size. Agency pages roll up awarding agencies. Source: USAspending.gov assistance awards.

Cardiovascular research as an extramural stock

Cardiovascular Diseases Research, CFDA 93.837, shows $24,340,828,120.12 in obligations, 11,285 awards, 920 recipients, and 51 states on USAspending.gov. About $2.16 million per award and about 12 awards per recipient on simple averages place this listing with other large extramural research CFDAs. Eleven thousand two hundred eighty-five rows include supplements and competing renewals as stored; that is why award count runs ahead of the 920 named organizations.

Fifty-one states in the geographic count is a nationwide-minus-a-few-labels pattern. It does not allocate dollars by heart-disease mortality. Place-of-performance follows coded recipient locations, which can cluster in research metros even when 51 state labels appear. The packet reports the count, not a public-health burden index.

Do not add other disease-research listings into the $24.3 billion. Do not treat 11,285 awards as trials completed. Do not treat the stock as outlays. The program page overlays 93.837; the programs index ranks it; agency pages may include this CFDA among other research listings. Source: USAspending.gov assistance awards.

Questions

How much is obligated for cardiovascular diseases research?

USAspending.gov records $24,340,828,120.12 in obligations for CFDA 93.837. SpendingVault indexes 11,285 awards, 920 recipients, and 51 states. The figure is an obligation sum from assistance awards, not an outlay and not a count of clinical trials. CFDA 93.837’s $24.3 billion on 11,285 awards and 920 recipients is the USAspending obligation stock.

How many organizations receive CFDA 93.837 awards?

The extract lists 920 recipients against 11,285 awards. That is about 12 award records per recipient on a simple average. An even split of $24.3 billion would be about $26.5 million per recipient; actual portfolios are uneven. Names are on the program page.

Does 51 states mean research funding matches heart-disease rates?

No. Fifty-one states appear in the USAspending geographic count. That reports how many state labels are attached to 93.837 awards. It does not allocate dollars by mortality or hospitalization. Place-of-performance often follows research institutions. CFDA 93.837’s $24.3 billion on 11,285 awards and 920 recipients is the USAspending obligation stock.

Is $24.3 billion already spent on cardiovascular research?

Not necessarily. Obligations are commitments on assistance awards tagged 93.837. Outlays are payments as institutions draw. This page reports the obligation stock from USAspending.gov and does not publish cash-paid or remaining-balance figures. CFDA 93.837’s $24.3 billion on 11,285 awards and 920 recipients is the USAspending obligation stock.